Daiichi Sankyo posts 'extraordinary loss' of nearly $1B
Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising demand for its ADCs to third-party manufacturers. The Japanese company ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · JP
- [CONFLICT] Japan-made EVs at risk of losing EU subsidies under content proposal
- [CONFLICT] US investors cite 3 ways Japanese equities can unlock more value
- [CONFLICT] Japan to let companies shield directors from big liability claims
- [NATURAL] M 4.6 - 117 km ENE of Miyako, Japan
- [CONFLICT] Swiatek's new coach tears Achilles as she and Osaka progress at Italian Open
- [CONFLICT] NTT punts profit target by 3 years as Japan mobile unit Docomo struggles